Business Description
Scandion Oncology A/S
ISIN : DK0061031895
Share Class Description:
FRA:8VY: Ordinary SharesCompare
Compare
Traded in other countries / regions
SCOL.Sweden8VY.Germany IPO Date
2021-02-09Description
Scandion Oncology A/S is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer that is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 63.08 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -19.9 | |||||
| 3-Year EPS without NRI Growth Rate | -26.1 | |||||
| 3-Year FCF Growth Rate | -34.8 | |||||
| 3-Year Book Growth Rate | -44.3 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.58 | |||||
| 9-Day RSI | 37.02 | |||||
| 14-Day RSI | 34.48 | |||||
| 6-1 Month Momentum % | -16.53 | |||||
| 12-1 Month Momentum % | -12.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.64 | |||||
| Quick Ratio | 7.64 | |||||
| Cash Ratio | 5.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.2 | |||||
| Shareholder Yield % | 2.18 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -89.49 | |||||
| ROA % | -76.39 | |||||
| ROIC % | -366.8 | |||||
| ROC (Joel Greenblatt) % | -1914.15 | |||||
| ROCE % | -100.66 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.8 | |||||
| Price-to-Tangible-Book | 2.66 | |||||
| EV-to-EBIT | -0.82 | |||||
| EV-to-EBITDA | -0.82 | |||||
| EV-to-Forward-EBITDA | -0.06 | |||||
| EV-to-Forward-Revenue | 2.3 | |||||
| EV-to-FCF | -0.04 | |||||
| Price-to-Net-Current-Asset-Value | 2.66 | |||||
| Price-to-Net-Cash | 5.32 | |||||
| Earnings Yield (Greenblatt) % | -121.76 | |||||
| FCF Yield % | -82.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Scandion Oncology A/S Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.038 | ||
| Beta | 2.74 | ||
| Volatility % | 187.48 | ||
| 14-Day RSI | 34.48 | ||
| 14-Day ATR (€) | 0.013929 | ||
| 20-Day SMA (€) | 0.089274 | ||
| 12-1 Month Momentum % | -12.29 | ||
| 52-Week Range (€) | 0.0168 - 0.4245 | ||
| Shares Outstanding (Mil) | 134.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Scandion Oncology A/S Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Scandion Oncology A/S Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Scandion Oncology A/S Frequently Asked Questions
What is Scandion Oncology A/S(FRA:8VY)'s stock price today?
The current price of FRA:8VY is €0.05. The 52 week high of FRA:8VY is €0.42 and 52 week low is €0.02.
When is next earnings date of Scandion Oncology A/S(FRA:8VY)?
The next earnings date of Scandion Oncology A/S(FRA:8VY) is 2024-08-29.
Does Scandion Oncology A/S(FRA:8VY) pay dividends? If so, how much?
Scandion Oncology A/S(FRA:8VY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers